DE69528170T2 - Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen - Google Patents

Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen

Info

Publication number
DE69528170T2
DE69528170T2 DE69528170T DE69528170T DE69528170T2 DE 69528170 T2 DE69528170 T2 DE 69528170T2 DE 69528170 T DE69528170 T DE 69528170T DE 69528170 T DE69528170 T DE 69528170T DE 69528170 T2 DE69528170 T2 DE 69528170T2
Authority
DE
Germany
Prior art keywords
virosomes
therapeutic substances
intracellular administration
therapeutic compounds
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69528170T
Other languages
English (en)
Other versions
DE69528170D1 (de
Inventor
C Wilschut
Peter Scherrer
Arcadio Chonn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bestewil Holding Bv Amsterdam Nl
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Publication of DE69528170D1 publication Critical patent/DE69528170D1/de
Application granted granted Critical
Publication of DE69528170T2 publication Critical patent/DE69528170T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Botany (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69528170T 1994-05-31 1995-05-31 Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen Expired - Lifetime DE69528170T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25146994A 1994-05-31 1994-05-31
PCT/CA1995/000321 WO1995032706A1 (en) 1994-05-31 1995-05-31 Virosome-mediated intracellular delivery of therapeutic agents

Publications (2)

Publication Number Publication Date
DE69528170D1 DE69528170D1 (de) 2002-10-17
DE69528170T2 true DE69528170T2 (de) 2003-05-22

Family

ID=22952103

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69528170T Expired - Lifetime DE69528170T2 (de) 1994-05-31 1995-05-31 Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen

Country Status (7)

Country Link
EP (1) EP0762870B1 (de)
JP (1) JPH10505320A (de)
AT (1) ATE223701T1 (de)
AU (1) AU2520595A (de)
CA (1) CA2191750C (de)
DE (1) DE69528170T2 (de)
WO (1) WO1995032706A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0850064A1 (de) * 1995-09-14 1998-07-01 Lxr Biotechnology Inc. Anti-apoptose zusammensetzung die eine mischung von phospholipiden enthält
NZ332666A (en) * 1996-05-08 2000-05-26 Nika Health Products Ltd Cationic virosomes having a positively charged lipid bilayer membrane with an integrated viral fusogenic peptide as genetic transfer systems for use in gene therapy
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP1390046A4 (de) 1999-04-15 2005-04-20 Wellstat Biologics Corp Behandlung von neoplasmen mit viren
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
JP4497894B2 (ja) * 2003-11-07 2010-07-07 明彦 河合 物質導入剤およびその製造方法
EP1773303A2 (de) 2004-05-25 2007-04-18 Chimeracore, Inc. Selbstmontierendes nanopartikel-wirkstofffreisetzungssystem
PL1802746T3 (pl) 2004-10-27 2011-10-31 Crucell Switzerland Ag Cząstki wirosomu zawierające antygeny wirusa grypy i wirusa zapalenia wątroby typu B
JP2009533350A (ja) * 2006-04-07 2009-09-17 キメロス， インコーポレイテッド Ｂ細胞悪性疾患を処置するための組成物および方法
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
EP2747774A4 (de) 2011-09-09 2015-02-11 Biomed Realty L P Verfahren und zusammensetzungen zur kontrolle einer virusproteinassemblierung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
US5292524A (en) * 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus

Also Published As

Publication number Publication date
EP0762870A1 (de) 1997-03-19
ATE223701T1 (de) 2002-09-15
DE69528170D1 (de) 2002-10-17
AU2520595A (en) 1995-12-21
JPH10505320A (ja) 1998-05-26
CA2191750C (en) 2008-06-10
WO1995032706A1 (en) 1995-12-07
CA2191750A1 (en) 1995-12-07
EP0762870B1 (de) 2002-09-11

Similar Documents

Publication Publication Date Title
DE69528170D1 (de) Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
MX9203439A (es) Una citocina mamifera, il-11
DK85786D0 (da) Biologisk aktive fragmenter af human antihaemofilisk faktor og fremgangsmaade til fremstilling deraf
NO862095L (no) Farmasoeytiske preparater inneholdende vevsplasmnogenaktivitator og fremgangsmaate for deres fremstilling.
NO962791L (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
NO993709D0 (no) Stabilisert blanding omfattende fibrinogen
ES2042693T5 (es) Formulaciones de proteinas plasmaticas y recombinantes en medios de baja potencia ionica.
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
ES8602121A1 (es) Procedimiento para producir un vehiculo de expresion para la formacion de uroquinasa humana
DK1394179T3 (da) Fremgangsmåde til fremstilling af erythropoietin fri for animalske proteiner
NO862096L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator.
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
FR2577557B1 (fr) Peptides et derives peptidiques, leur preparation, leur utilisation en therapeutique et compositions pharmaceutiques les contenant
DK0539479T3 (da) Heterocykliske forbindelser
NO883834L (no) Nye hiv-proteiner og peptider anvendelige i diagnosen, profylaksen eller terapien av aids.
PT1131408E (pt) Acidos oligossacarido-aldonicos e sua utilizacao topica
FR2732978B1 (fr) Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DK0984983T3 (da) Modulatorer af intracellulære inflammations-, celledöds- og celleoverlevelsesforlöb indeholdende et CARD- og et kinasedomæne
EE200000538A (et) TNF/NGF retseptoriperekonna retseptorite ja muudevalkude talitluse modulaatorid, nende valmistamine ja kasutamine ning farmatseutiline kompositsioon
BRPI0209416A8 (pt) novos vetores de expressão e uso dos mesmos
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
IT1230483B (it) Procedimento per la produzione di una proteina endotossica, gene strutturale impiegato e composizioni insetticide comprendenti detta proteina
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
IT1251961B (it) Peptidi che rappresentano permutazioni della sequenza del mastoparano

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: UNIVERSITY OF GRONINGEN,FACULTY OF MEDICAL SCIENCE

8327 Change in the person/name/address of the patent owner

Owner name: BESTEWIL HOLDING B.V., AMSTERDAM, NL

8364 No opposition during term of opposition